U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517198) titled 'Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors' on March 27.
Brief Summary: The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Small Cell Lung Cancer (SCLC)
High Grade Neuroendocrine Cancer
Small Cell Carcinomas of Non-lung Origin
Non-small Cell Lung Cancer (NSCLC)
Prostate Cancer
Ovarian Cancer
Renal Carcinoma (Clear and Non-clear Cell)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Hepatic...